Related references
Note: Only part of the references are listed.Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice
S. T. Hasan et al.
ATHEROSCLEROSIS (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
CIRCULATION (2014)
Heart Disease and Stroke Statistics-2014 Update A Report From the American Heart Association
Alan S. Go et al.
CIRCULATION (2014)
Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis
Uwe J. F. Tietge
CURRENT OPINION IN LIPIDOLOGY (2014)
Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia
Congwu Huang et al.
LIPIDS IN HEALTH AND DISEASE (2014)
Endothelial dysfunction as a cellular mechanism for vascular failure
Tetsuaki Hirase et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2012)
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Alexios S. Antonopoulos et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Konstantinos Tziomalos et al.
CURRENT VASCULAR PHARMACOLOGY (2012)
Cardioprotection from oxidative stress in the newborn heart by activation of PPARγ is mediated by catalase
Tao Chen et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
Pitchai Balakumar et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Davide Grassi et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Endothelial Dysfunction in the Apolipoprotein E-deficient Mouse: insights into the influence of diet, gender and aging
Silvana S. Meyrelles et al.
LIPIDS IN HEALTH AND DISEASE (2011)
PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation
Yusheng Ren et al.
VASCULAR PHARMACOLOGY (2009)
Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: Are the reagents beneficial or harmful?
Rui Chen et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Safety issues and prospects for future generations of PPAR modulators
Anne Rubenstrunk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Cardioprotection mediated by rosiglitazone, a peroxisome proliferatoractivated receptor gamma ligand, in relation to nitric oxide
Adrian T. Gonon et al.
BASIC RESEARCH IN CARDIOLOGY (2007)
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK
Behzad Molavi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
PPARγ in endothelial cells influences high fat diet-induced hypertension
CJ Nicol et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury
TL Yue et al.
DIABETES (2005)
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells
F Mulhaupt et al.
CARDIOVASCULAR RESEARCH (2003)
PPAR agonists in the treatment of atherosclerosis
GA Francis et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells
DS Calnek et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
15-deoxy-Δ12,14-prostaglandin J2 -: A prostaglandin D2 metabolite generated during inflammatory processes
T Shibata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes
O Grip et al.
INFLAMMATION RESEARCH (2002)
Peroxisome proliferator-activated receptors in the cardiovascular system
D Bishop-Bailey
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
